Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Arthritis & Rheumatism

• Publication date

  1998-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-IPMID 9550476
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Scleroderma Autoantigens Are Uniquely Fragmented by Metal-catalyzed Oxidation Reactions: Implications for Pathogenesis

  1997cited by this paper
• SYSTEMIC SCLEROSIS : A Vascular Perspective

  1996cited by this paper
• Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes.

  1996cited by this paper
• Raynaud's phenomenon.

  1996cited by this paper
• Modulation of Collagen Gene Expression: Its Relation to Fibrosis in Systemic Sclerosis and Other Disorders

  1995cited by this paper
• Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study.

  1995cited by this paper
• Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon.

  1994cited by this paper
• Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study

  1994cited by this paper
• A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.

  1993cited by this paper
• Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon.

  1992cited by this paper
• Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.

  1992cited by this paper
• Why everything (or nothing) seems to work in the treatment of scleroderma.

  1992cited by this paper
• Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon.

  1991cited by this paper
• Successful treatment of Raynaud's phenomenon with limaprost, an oral prostaglandin E1 analogue.

  1991cited by this paper
• The endothelium: its role in scleroderma.

  1991cited by this paper
• A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.

  1991cited by this paper
• International study of ketanserin in Raynaud's phenomenon.

  1989cited by this paper
• Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.

  1989cited by this paper
• Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.

  1988cited by this paper
• Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.

  1988cited by this paper
• Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis.

  1987cited by this paper
• Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.

  1983cited by this paper
• INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROME: A Double-blind Controlled Trial

  1983cited by this paper
• Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2)

  1982cited by this paper
• Successful Treatment of Raynaud's Syndrome with Prostacyclin

  1981cited by this paper
• Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon.

  1980cited by this paper
• Preliminary criteria for the classification of systemic sclerosis (scleroderma).

  1980cited by this paper
• Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

  1980cited by this paper
• Nonparametrics: Statistical Methods Based on Ranks

  1975cited by this paper
• HUMAN ALBUMIN POLYMERS

  1974cited by this paper

• Raynaud's phenomenon and digital ulceration in systemic sclerosis.

  2026cites this paper
• State-of-the-Art Overview of Diagnosis and Treatment of Raynaud’s Phenomenon

  2025cites this paper
• Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue–Related Raynaud Phenomenon in the United States

  2025cites this paper
• Systematic literature review to inform the Portuguese recommendations for the management of Raynaud's phenomenon and digital ulcers in systemic sclerosis and other connective tissue diseases.

  2024cites this paper
• 2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis

  2024cites this paper
• The Efficacy and Tolerability of Prostaglandin Analogues in Treating Systemic Sclerosis-Associated Raynaud Phenomenon: A Systematic Review and Meta-Analysis

  2024cites this paper
• Heating of the neck or elbows alleviates Raynaud's phenomenon but has different effects on different types of patients with systemic sclerosis.

  2023cites this paper
• Construct validity and reliability of the assessment of systemic sclerosis-associated raynaud's phenomenon (ASRAP) questionnaire.

  2023cites this paper
• Domain reporting in systemic sclerosis-related Raynaud's phenomenon: An OMERACT scoping review.

  2023cites this paper
• Assessment of the Systemic Sclerosis–Associated Raynaud's Phenomenon Questionnaire: Item Bank and Short‐Form Development

  2022cites this paper
• Raynaud’s Phenomenon with Focus on Systemic Sclerosis

  2022cites this paper
• Arm heating to relieve Raynaud's phenomenon in systemic sclerosis: A single-arm multicentre prospective clinical trial.

  2022cites this paper
• Proximal heat stress up-regulates angiopoietin-1 in fingers and reduces the severity of Raynaud's phenomenon in systemic sclerosis: a single-centre pilot study.

  2021cites this paper
• Systemic sclerosis: a rare presentation

  2021cites this paper
• Ulcérations et nécroses digitales du membre supérieur

  2021cites this paper
• Raynaud’s phenomenon and related vasospastic disorders

  2021cites this paper
• TCRM_A_219024 1427..1442

  2019cites this paper
• Factors Influencing Raynaud Condition Score Diary Outcomes in Systemic Sclerosis

  2019cites this paper
• The patient experience of Raynaud’s phenomenon in systemic sclerosis

  2019cites this paper
• Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient‐Reported Assessments of Disease Severity

  2019cites this paper
• Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon: A Feasibility Study

  2019cites this paper
• Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis

  2019cites this paper
• Factors influencing Raynaud’s condition score diary outcomes in systemic sclerosis

  2019cites this paper
• Management of Raynaud’s phenomenon in systemic sclerosis—a practical approach

  2019cites this paper
• French translation and linguistic validation of the Raynaud's condition score.

  2019cites this paper
• Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH)

  2019cites this paper
• Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials.

  2019cites this paper
• Patient-reported outcome instruments in clinical trials of systemic sclerosis

  2019cites this paper
• Patient-reported outcome instruments for assessing Raynaud’s phenomenon in systemic sclerosis: A SCTC vascular working group report

  2018cites this paper
• An interim report of the Scleroderma Clinical Trials Consortium working groups

  2018cites this paper
• Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts

  2018cites this paper
• Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis

  2018influential citation
• The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis

  2018cites this paper
• Analyse von Anti-Topoisomerase I-Antikörpern und Evaluierung ihrer immundominanten Epitope bei Patienten mit diffus kutaner systemischer Sklerose vor und nach autologer hämatopoetischer Stammzelltransplantation

  2018cites this paper
• Behaviour change interventions for the management of Raynaud’s phenomenon: a systematic literature review

  2018cites this paper
• Pharmacotherapy Options in the Management of Raynaud’s Phenomenon

  2018cites this paper
• Establishing treatment efficacy for cutaneous vascular manifestations of SSc

  2018influential citation
• Raynaud’s Phenomenon and Ulcers

  2018cites this paper
• Systemic sclerosis: Current concepts of skin and systemic manifestations.

  2018cites this paper
• The Effects of Exercise on Vascular Physiologyin Systemic Sclerosis Patients

  2018cites this paper
• Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

  2017cites this paper
• Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study.

  2017cites this paper
• Points to consider—Raynaud’s phenomenon in systemic sclerosis

  2017cites this paper
• Patient participation in patient-reported outcome instrument development in systemic sclerosis.

  2017cites this paper
• Raynaud’s Phenomenon, Digital Ulcers and Nailfold Capillaroscopy

  2017cites this paper
• Use of intravenous epoprostenol as a treatment for the digital vasculopathy associated with the scleroderma spectrum of diseases

  2017cites this paper
• Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up

  2017cites this paper
• Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: An evolutional database model of validated patient-reported outcomes.

  2017cites this paper
• Therapeutic implications from the pathogenesis of Raynaud’s phenomenon

  2017cites this paper
• Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames)

  2017cites this paper
• Clinical Trial Design in Systemic Sclerosis

  2017cites this paper
• A randomized controlled trial of acupressure for the treatment of Raynaud's phenomenon: the difficulty of conducting a trial in Raynaud's phenomenon

  2016influential citation
• Raynaud's phenomenon.

  2016cites this paper
• Chapter 31 – Raynaud Phenomenon and Vasomotor Syndromes

  2016cites this paper
• The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase‐1 antibodies

  2016cites this paper
• Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary

  2015cites this paper
• Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.

  2015cites this paper
• Management of Digital Ischemia

  2015cites this paper
• ¿Es efectivo el iloprost en el fenómeno de Raynaud secundario? Is iloprost effective in secondary Raynaud's phenomenon?

  2015influential citation
• Management of Systemic Sclerosis-Related Skin Disease: A Review of Existing and Experimental Therapeutic Approaches.

  2015cites this paper
• Management of Systemic Sclerosis-Related Skin

  2015cites this paper
• Update of EULAR recommendations for the treatment of systemic sclerosis

  2015cites this paper
• Efficacy of Raynaud’s phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review

  2015cites this paper
• Non-pharmacological care for patients with systemic sclerosis

  2015influential citation
• Design and Reporting of Randomised Controlled Trials for Raynaud’s Phenomenon

  2015cites this paper
• ADVANCES IN THERAPIES FOR SYSTEMIC SCLEROSIS

  2015cites this paper
• Is iloprost effective in secondary Raynaud's phenomenon?

  2015cites this paper
• Optimal management of digital ulcers in systemic sclerosis

  2015cites this paper
• [Pharmacology of Raynaud's phenomenon].

  2014cites this paper
• Hand Function in Scleroderma

  2014cites this paper
• Evaluating digital vascular perfusion and platelet dysfunction in Raynaud's phenomenon and systemic sclerosis

  2014cites this paper
• Pharmacologie du phénomène de Raynaud

  2014cites this paper
• Oral N-acetylcysteine in the treatment of Raynaud ’ s phenomenon secondary to systemic sclerosis : A randomized , double-blind , placebo-controlled clinical trial

  2014cites this paper
• [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].

  2014cites this paper
• Raynaud syndrome.

  2014cites this paper
• Treatment options in Raynaud's phenomenon

  2014cites this paper
• Evaluation of Test Characteristics for Outcome Measures Used in Raynaud's Phenomenon Clinical Trials

  2013cites this paper
• Systemic Sclerosis: Current Concepts in Pathogenesis and Therapeutic Aspects of Dermatological Manifestations

  2013cites this paper
• Recommendations of the Brazilian Society of Rheumatology Recommendations for the management and treatment of systemic sclerosis

  2013cites this paper
• Systemic sclerosis—challenges for clinical practice

  2013cites this paper
• Current medical and surgical management of Raynaud's syndrome.

  2013cites this paper
• L’atteinte de la main dans la sclérodermie systémique

  2013cites this paper
• Anodal Iontophoresis of a Soluble Guanylate Cyclase Stimulator Induces a Sustained Increase in Skin Blood Flow in Rats

  2013cites this paper
• Treatment options in systemic sclerosis

  2013cites this paper
• Sjogren's syndrome.

  2013cites this paper
• Ulcération et nécrose digitale du membre supérieur

  2013cites this paper
• [Hand involvement in systemic sclerosis].

  2013cites this paper
• Complex Raynaud’s phenomenon: evolving concepts of management

  2013cites this paper
• Recomendações sobre diagnóstico e tratamento da esclerose sistêmica

  2013cites this paper
• Vasospastic Disease of the Upper Extremity: Primary Raynaud's Syndrome

  2012cites this paper
• The pathogenesis, diagnosis and treatment of Raynaud phenomenon

  2012cites this paper
• Very early diagnosis of systemic sclerosis.

  2012cites this paper
• Vasodilatory Therapeutics in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort

  2012cites this paper
• Scleroderma therapy: clinical overview of current trends and future perspective

  2012cites this paper
• Chapitre 39 - Pharmacologie et Thérapeutique Vasculaire

  2011cites this paper
• Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review.

  2011cites this paper
• Chapter 29 – RAYNAUD PHENOMENON AND VASOMOTOR SYNDROMES

  2011cites this paper
• Développement de la iontophorèse comme axe thérapeutique des atteintes microcirculatoires dans la sclérodermie systémique

  2011cites this paper
• Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.

  2011cites this paper
• Prise en charge du phénomène de Raynaud et des ulcères digitaux dans la sclérodermie systémique

  2011cites this paper